Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c

doi:10.4254/wjh.v10.i9.612

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 9

This Article

(296)

(304)

(0)

(16)

(4888)

(14)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Study

World J Hepatol. Sep 27, 2018; 10(9): 612-621
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.612

Table 2 Baseline characteristics of patients with hepatitis C virus and type 2 diabetes mellitus

	All patients (n = 106)	SVR12 not achieved (n = 8)	SVR12 achieved (n = 98)	P-value
Age (mean ± SD, yr)	63.2 ± 0.5	59.6 ± 1.4	63.5 ± 0.5	0.04
Sex
Male	99.1 (105)	7.60 (8)	92.40 (97)	0.74
Female	0.90 (1)	0.00 (0)	100.0 (1)	0.74
Race/ethnicity
White	27.40 (29)	6.90 (2)	93.20 (27)	0.15
African American	36.80 (39)	5.10 (2)	94.90 (37)
Hispanic	25.50 (27)	11.1 (3)	88.90 (24)
Asian	1.90 (2)	50.0 (1)	50.00 (1)
Other	8.50 (9)	0.00 (0)	100.0 (9)
Cirrhosis
Yes	53.80 (57)	8.80 (5)	91.20 (52)	0.61
No	46.20 (49)	6.10 (3)	93.90 (46)	0.61
CTP class
CTP A	82.50 (47)	6.40 (3)	93.60 (44)	0.21
CTP B	14.00 (8)	25.0 (2)	75.0 (6)
CTP C	3.50 (2)	0.00 (0)	100.0 (2)
Treatment status
Naive	67.90 (72)	5.60 (4)	94.40 (68)	0.26
Experienced	32.10 (34)	11.8 (4)	88.20 (30)	0.26
HCV genotype
Genotype 1a	56.60 (60)	10.0 (6)	90.00 (54)	0.67
Genotype 1b	22.60 (24)	4.20 (1)	95.80 (23)
Genotype 2	12.30 (13)	0.00 (0)	100.0 (13)
Genotype 3	7.60 (8)	12.5 (1)	87.50 (7)
Genotype 4	0.90 (1)	0.00 (0)	100.0 (1)
Treatment regimen
Sofosbuvir/Simeprevir	39.60 (42)	7.10 (3)	92.90 (39)	0.96
Sofosbuvir/Ribavirin	17.00 (18)	5.60 (1)	94.40 (17)
PrOD	18.90 (20)	10.0 (2)	90.00 (18)
Sofosbuvir/Ledipasvir	24.50 (26)	7.70 (2)	92.30 (24)
Body mass index
Normal	15.10 (16)	6.20 (1)	93.80 (15)	0.78
Overweight	41.50 (44)	9.10 (4)	90.90 (40)
Obese	28.30 (30)	6.70 (2)	93.30 (28)
Severely obese	10.40 (12)	8.30 (1)	91.70 (11)
Very severely obese	4.70 (4)	0.00 (0)	100.0 (4)
Co-HIV infection	2.80 (3)	100.0 (3)	0.0 (0)	0.62
HTN	89.60 (95)	8.40 (8)	91.60 (87)	0.32
HLD	74.50 (79)	6.30 (5)	93.70 (74)	0.42
Metabolic syndrome	80.20 (85)	7.10 (6)	92.90 (79)	0.71

HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; HTN: Hypertension; HLD: Hyperlipidemia; PrOD: Ombitasvir/Paritaprevir/Ritonavir/ Dasabuvir; SVR: Sustained virologic response; CTP: Child-Turcotte-Pugh.

Full Size Table

Citation: Dong TS, Aby ES, Benhammou JN, Kawamoto J, Han SH, May FP, Pisegna JR. Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c. World J Hepatol 2018; 10(9): 612-621
URL: https://www.wjgnet.com/1948-5182/full/v10/i9/612.htm
DOI: https://dx.doi.org/10.4254/wjh.v10.i9.612

Dong TS, Aby ES, Benhammou JN, Kawamoto J, Han SH, May FP, Pisegna JR. Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c. World J Hepatol 2018; 10(9): 612-621 [PMID: 30310539 DOI: 10.4254/wjh.v10.i9.612]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.